MA42134A - Conjugués peptides/oligonucléotides - Google Patents
Conjugués peptides/oligonucléotidesInfo
- Publication number
- MA42134A MA42134A MA042134A MA42134A MA42134A MA 42134 A MA42134 A MA 42134A MA 042134 A MA042134 A MA 042134A MA 42134 A MA42134 A MA 42134A MA 42134 A MA42134 A MA 42134A
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- oligonucleotides conjugates
- conjugates
- oligonucleotides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163960P | 2015-05-19 | 2015-05-19 | |
| US201662337536P | 2016-05-17 | 2016-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42134A true MA42134A (fr) | 2018-03-28 |
Family
ID=57320822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042134A MA42134A (fr) | 2015-05-19 | 2016-05-19 | Conjugués peptides/oligonucléotides |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10675356B2 (fr) |
| EP (2) | EP3297649B1 (fr) |
| JP (2) | JP6954843B2 (fr) |
| KR (2) | KR102644053B1 (fr) |
| CN (2) | CN114681621B (fr) |
| AU (1) | AU2016264471B2 (fr) |
| CA (1) | CA2986228A1 (fr) |
| DK (1) | DK3297649T5 (fr) |
| ES (1) | ES2964695T3 (fr) |
| FI (1) | FI3297649T3 (fr) |
| HK (1) | HK1252759A1 (fr) |
| HR (1) | HRP20231431T1 (fr) |
| IL (1) | IL255655B (fr) |
| MA (1) | MA42134A (fr) |
| MX (1) | MX388743B (fr) |
| NZ (1) | NZ737757A (fr) |
| WO (1) | WO2016187425A1 (fr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| CN109757108A (zh) | 2016-07-05 | 2019-05-14 | 比奥马林技术公司 | 具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸 |
| SG10202107429WA (en) * | 2017-01-06 | 2021-08-30 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| KR102279333B1 (ko) | 2017-03-07 | 2021-07-20 | 주식회사 만도 | 차량의 디스플레이 시스템 및 이의 구동 방법 |
| GB2580569B (en) * | 2017-06-28 | 2021-08-18 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| JP2020537497A (ja) * | 2017-09-22 | 2020-12-24 | アビディティー バイオサイエンシーズ，インク． | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
| JP7356416B2 (ja) * | 2017-10-17 | 2023-10-04 | サレプタ セラピューティクス， インコーポレイテッド | 二環式ペプチドオリゴヌクレオチドコンジュゲート |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US12168059B2 (en) * | 2018-07-30 | 2024-12-17 | Sarepta Therapeutics, Inc. | Trimeric peptides for antisense delivery |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (fr) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| EP3959319A4 (fr) | 2019-04-25 | 2023-06-07 | Avidity Biosciences, Inc. | Compositions d'acide nucléique et méthodes de saut multi-exon |
| JP7581252B2 (ja) | 2019-06-06 | 2024-11-12 | アビディティー バイオサイエンシーズ，インク． | Ｕｎａアミダイトおよびその使用 |
| US11578090B2 (en) | 2019-06-06 | 2023-02-14 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| AU2020411964A1 (en) | 2019-12-26 | 2022-06-16 | National Center Of Neurology And Psychiatry | Antisense nucleic acid that induces skipping of exon 50 |
| PE20230237A1 (es) | 2020-02-28 | 2023-02-07 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido que inducen la omision del exon 51 |
| AU2021237465A1 (en) | 2020-03-19 | 2022-10-13 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| US20250302979A1 (en) * | 2021-04-02 | 2025-10-02 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping |
| AU2022298028A1 (en) | 2021-06-23 | 2023-12-21 | National Center Of Neurology And Psychiatry | Combination of antisense oligomers |
| WO2023282346A1 (fr) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | Inhibiteur de précipitation |
| JPWO2023282344A1 (fr) | 2021-07-08 | 2023-01-12 | ||
| IL310003A (en) | 2021-07-08 | 2024-03-01 | Nippon Shinyaku Co Ltd | Nephrotoxicity reducing agent |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP4370677A1 (fr) | 2021-07-16 | 2024-05-22 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Oligonucléotide pour inhiber l'activité de tremblement |
| CN118265544A (zh) | 2021-09-16 | 2024-06-28 | 艾维迪提生物科学公司 | 治疗面肩肱型肌营养不良的组合物和方法 |
| CN120129745A (zh) | 2022-03-10 | 2025-06-10 | 日本新药株式会社 | 抗病毒反义低聚物 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| JP2025515168A (ja) | 2022-05-06 | 2025-05-13 | アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム | オリゴヌクレオチド |
| EP4594520A2 (fr) | 2022-09-30 | 2025-08-06 | Sixfold Bioscience Ltd. | Compositions contenant des oligonucléotides ayant des applications théranostiques |
| CN121569035A (zh) * | 2023-07-04 | 2026-02-24 | 大睿生物医药科技(上海)有限公司 | 包含肽的寡核苷酸递送配体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| AU5661386A (en) | 1985-03-15 | 1986-10-13 | Stirchak, E. | Stereoregular polynucleotide-binding polymers |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US6559279B1 (en) * | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| CA2884340C (fr) | 2007-11-15 | 2017-07-25 | Sarepta Therapeutics, Inc. | Procede de synthese d'oligomeres morpholino |
| WO2010048568A1 (fr) * | 2008-10-23 | 2010-04-29 | Targeted Growth, Inc. | Micro-organismes photosynthétiques modifiés pour la production de triglycérides |
| EP2762567B1 (fr) * | 2008-10-24 | 2016-07-13 | Sarepta Therapeutics, Inc. | Compositions de saut d'exon multiples pour dmd |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| ES2574625T3 (es) * | 2009-11-25 | 2016-06-21 | Elitechgroup B.V. | Antagonistas de miARN de oligonucleótido conjugado con aglutinante del surco menor (MGB) |
| CN102712927B (zh) * | 2009-12-16 | 2017-12-01 | 库尔纳公司 | 通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病 |
| PL2623507T3 (pl) | 2010-09-30 | 2017-03-31 | Nippon Shinyaku Co., Ltd. | Pochodna kwasu morfolinonukleinowego |
| EP2699269A1 (fr) * | 2011-04-22 | 2014-02-26 | Prosensa Technologies B.V. | Nouveaux composés pour traiter, retarder et/ou prévenir un trouble génétique humain, tel que la dystrophie myotonique de type 1 (dm1) |
| WO2012150960A1 (fr) * | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Conjugués peptides/oligonucléotides |
| EP2785729B1 (fr) | 2011-11-30 | 2020-11-04 | Sarepta Therapeutics, Inc. | Oligonucléotides pour le traitement de maladies à répétition étendue |
| PT2788487T (pt) * | 2011-12-08 | 2018-07-03 | Sarepta Therapeutics Inc | Análogos de oligonucleótido visando lmna humano |
| CA2868174A1 (fr) * | 2012-03-20 | 2013-09-26 | Sarepta Therapeutics, Inc. | Conjugues d'acide boronique d'analogues oligonucleotides |
| AU2013285698A1 (en) * | 2012-07-03 | 2015-02-19 | Biomarin Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
| MX369519B (es) * | 2012-09-25 | 2019-11-11 | Genzyme Corp | Oligonucleotidos antisentido morfolino unidos a peptido para el tratamiento de distrofia miotonica. |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| US20180216111A1 (en) | 2015-02-27 | 2018-08-02 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
-
2016
- 2016-05-19 US US15/574,734 patent/US10675356B2/en active Active
- 2016-05-19 WO PCT/US2016/033276 patent/WO2016187425A1/fr not_active Ceased
- 2016-05-19 KR KR1020177035825A patent/KR102644053B1/ko active Active
- 2016-05-19 EP EP16797300.7A patent/EP3297649B1/fr active Active
- 2016-05-19 HR HRP20231431TT patent/HRP20231431T1/hr unknown
- 2016-05-19 CN CN202210279461.1A patent/CN114681621B/zh active Active
- 2016-05-19 DK DK16797300.7T patent/DK3297649T5/da active
- 2016-05-19 CN CN201680041867.9A patent/CN107921092B/zh active Active
- 2016-05-19 NZ NZ737757A patent/NZ737757A/en unknown
- 2016-05-19 JP JP2017560238A patent/JP6954843B2/ja active Active
- 2016-05-19 CA CA2986228A patent/CA2986228A1/fr active Pending
- 2016-05-19 EP EP23195508.9A patent/EP4306538A3/fr active Pending
- 2016-05-19 MX MX2017014806A patent/MX388743B/es unknown
- 2016-05-19 KR KR1020247007058A patent/KR20240035901A/ko active Pending
- 2016-05-19 HK HK18112084.2A patent/HK1252759A1/zh unknown
- 2016-05-19 FI FIEP16797300.7T patent/FI3297649T3/fi active
- 2016-05-19 ES ES16797300T patent/ES2964695T3/es active Active
- 2016-05-19 MA MA042134A patent/MA42134A/fr unknown
- 2016-05-19 AU AU2016264471A patent/AU2016264471B2/en active Active
-
2017
- 2017-11-14 IL IL255655A patent/IL255655B/en unknown
-
2020
- 2020-04-28 US US16/860,292 patent/US11097011B2/en active Active
- 2020-11-05 JP JP2020185083A patent/JP2021011505A/ja active Pending
-
2021
- 2021-08-16 US US17/403,403 patent/US11672871B2/en active Active
-
2023
- 2023-04-06 US US18/296,697 patent/US12239715B2/en active Active
-
2025
- 2025-01-17 US US19/029,784 patent/US20260014263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42134A (fr) | Conjugués peptides/oligonucléotides | |
| IL255217A0 (en) | Cancer neoepitopes | |
| EP3313857A4 (fr) | Conjugués polymère-cyclodextrine-lipide | |
| LT3525830T (lt) | Pirolbenzodiazepino konjugatai | |
| DK3268047T3 (da) | Amatoxin/antistof-konjugater | |
| EP3408391A4 (fr) | Oligonucléotides ramifiés | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| EP3314027A4 (fr) | Oligonucléotides thérapeutiques | |
| IL254516B (en) | Proteins specific for cd137 | |
| EP3328873A4 (fr) | Oligonucléotides ciblés | |
| DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
| PT3496173T (pt) | Material de perovskita | |
| DK3119885T3 (da) | Antistof-fynomer-konjugater | |
| LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
| DK3148591T3 (da) | Nanopartikel-lægemiddelkonjugater | |
| DK3067559T3 (da) | Inflator | |
| EP3355931C0 (fr) | Conjugués de protéines | |
| DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
| IL284753A (en) | Oligonucleotide peptide conjugates | |
| IL253549B (en) | Antibody-urease conjugates for therapeutic purposes | |
| PL3316885T3 (pl) | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a | |
| DK3544634T3 (da) | MET-antistof-lægemiddelkonjugater | |
| EP3619311C0 (fr) | Assemblage d'adn | |
| DK3448879T3 (da) | Claudin-6 peptider | |
| DK3329004T3 (da) | Terapeutiske oligonukleotider |